copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home - Purespring Therapeutics At Purespring, we are reimaging gene therapy delivery for kidney diseases, developing precisely targeted low-dose therapies that minimise systemic effects and deliver durable efficacy to transform the disease’s trajectory for patients
Purespring Therapeutics presents new preclinical data on novel gene . . . Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated virus (AAV) gene therapy platform
People - Purespring Therapeutics Purespring is a fully integrated company, with the building blocks in place to move rapidly through clinical validation to transform the treatment of kidney diseases as rapidly as possible
Purespring Therapeutics presents preclinical data at the 61st ERA . . . Purespring seeks to advance gene therapies for the treatment of both monogenic and non-monogenic chronic renal diseases that are currently poorly addressed with existing treatments For more information please visit: purespringtx com and follow us on LinkedIn
Purespring Therapeutics raises £80 $105 million in a Series B financing . . . Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform
About - Purespring Therapeutics Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery
Purespring Therapeutics receives UK CTA approval for Phase I II . . . Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery
Purespring Therapeutics granted European Medicines Agency (EMA) orphan . . . Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal disease, through its proprietary adeno-associated viral (AAV) gene therapy platform